OCUP - Ocuphire Pharma to Present in the BIO CEO & Investor Conference | Benzinga
FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP) ("Ocuphire"), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A, M.S. CEO of Ocuphire, will be presenting a company overview at the BIO CEO & Investor Conference being held February 26-27 2024 in New York City. Company management will also be participating in one-on-one meetings throughout the conference.
| BIO CEO & Investor Conference – February 26-27, 2024 |
| Title: |
| Ocuphire Pharma, Inc. (OCUP) Company Presentation |
| Presenter: |
| George Magrath, M.D. M.B.A, M.S. |
| Date: |
| Tuesday, February 27, 2024 |
| Time: |
| 2:45 – 3:00pm ET |
| Location: |
| Plymouth Room, Marriott Marquis, New York, NY |
If you are interested in arranging a 1x1 meeting, please contact your conference representative or send an email to ir@ocuphire.com. For more details, please see the Investors and Events section of Ocuphire's corporate website.
About Ocuphire Pharma
Ocuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders.
Ocuphire's lead retinal product candidate, APX3330, is a first-in-class small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref-1 is a regulator of the transcription factors HIF-1? and NF-?B. Inhibiting REF-1 reduces levels of vascular endothelial growth factor ("VEGF") and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. Through inhibition of Ref-1, APX3330 normalizes the ...